A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma Mobasher, M., Miller, R. A., Janc, J. W., Kwei, L., Buggy, J. J., Luciano, G., Mohammady, A., Kim, W., Kim, Y. H., Khodadoust, M. S., Horwitz, S. M., Radeski, D. AMER SOC HEMATOLOGY. 2019

View details for DOI 10.1182/blood-2019-124958

View details for Web of Science ID 000577164602053